A Clinical Flow-Chart for the “Treatment-Resistant Smoker”

Slides:



Advertisements
Similar presentations
NC STEP/Mission Hospitals School Cessation and Treatment Guide.
Advertisements

Jean-François ETTER Evelyne LASZLO Jean-Pierre ZELLWEGER Charles PERROT Thomas PERNEGER University of Geneva, Switzerland Smoking reduction with NRT: a.
Quitting smoking is always the best option, however, some smokers are not yet ready or willing to quit and continue to inflict harm on themselves and the.
STAGES OF CHANGE Precontemplation Contemplation Action Maintenance Relapse Not yet considering quitting Thinking about quitting Making a quit attempt Remaining.
A Virtual Arm to Stop Smoking A comparative study B. Girard 1, V. Turcotte 1 and S. Bouchard 2 1.GRAP, Occupational psychology clinic Saguenay (Québec)
Treating Tobacco Dependence Ask your patients about tobacco use Act to help them quit.
ABCs of Behavioral Support Jonathan Foulds PhD. Penn State – College of Medicine
Treatment of Tobacco Dependence in 2012 J. Taylor Hays, MD Professor of Medicine Associate Director Nicotine Dependence Center Mayo Clinic Rochester, MN.
Quit Information Seminar. Aims of session To: help you to understand why people smoke provide information about quitting methods and products discuss.
Presinted by :Shahd Amer.  Tobacco ads may make you feel like everyone is doing it but they are not.  Only about 28% of high school students smoke.
Nicotine Replacement Therapy: Administration and Overview Barbara Hart, MPA and Claudia Lechuga, MS Bronx BREATHES T: (718) E:
Prevention strategies
Smoking Cessation. Opportunity for Physicians 70 percent of smokers want to quit. Without assistance only 5 percent are able to quit. Most try to quit.
Treating Nicotine Dependence in Patients with Addictive Disorders Eric Heiligenstein, M.D. Director of Psychiatry University Health Services University.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2015.
1 CTRI Webinar: Combination Medication Effectiveness June 9, 2010 Stevens S. Smith, Ph.D. Megan E. Piper, Ph.D. Center for Tobacco Research & Intervention.
1 Obesity Treatment in Special Populations Smokers –All smokers, regardless of weight, should quit smoking. –Implement weight gain prevention, treatment.
Clinical aspects of smoking cessation Jean-Pierre Zellweger, MD Swiss Lung Association and Int. Union against TB and Lung Disease (The Union)
What we need to know about smoking & tobacco addiction.
Nicotine-related disorders Answers obtained from DSM-IV-TR and the AJP Supplement of August, 2006, on substance abuse As of 1Sep08.
Quit Information Seminar. Aims of session To: help you to understand why people smoke provide information about quitting methods and products discuss.
Le rôle de la réduction de dommages dans la lutte antitabac The role of harm reduction in tobacco control Lars M. Ramström Institute for Tobacco Studies.
Real-world effectiveness of nicotine replacement therapy in pregnancy Leonie S. Brose, PhD Andy McEwen, PhD & Robert West, PhD University College London.
Why People with Mental Health Conditions Smoke So Much and What To Do About It John Hughes University of Vermont, USA
Implementing the NICE guidelines for smoking cessation in secondary care: From rhetoric to reality Debbie Robson & Ann McNeill Addictions Department, Institute.
An Updated Algorithm for Choosing Among Smoking Cessation Treatments John R. Hughes University of Vermont, USA
Number of deaths (’000s) in 1998 attributable to tobacco use WHO Region Males Females World Health Report 1999 All member states3, Africa 112.
Group vs. individual therapy – which is best? Andy McEwen CRUK Health Behaviour Unit University College London.
Laws/Policies ABSTRACT Problem: A challenge for tobacco control practitioners is getting smokers to quit using cessation methods. To increase the proportion.
Increasing Access to Pharmacotherapy Jonathan P. Winickoff, MD, MPH Associate Professor in Pediatrics Harvard Medical School April 26, 2013.
Nicotine dependence It’s in ICD 10! MRCPsych addiction psychiatry seminars March 2010.
Tobacco Cessation Strategies and Resources: Epidemiology, Evidence and Availability May 29, 2013 The National Tobacco-Free College Campus Initiative: Building.
Effects of a combination of varenicline and nicotine patch on post-quitting urges to smoke Katie Myers Smith BSc MSc CPsychol Research Fellow Wolfson Institute.
Addressing Nicotine Dependence in Drug Treatment Kimber Paschall Richter, PhD, MPH Robert M. McCool, MS University of Kansas School of Medicine, Kansas.
Attempting to increase the use of smoking cessation medications Brendon Baker Ministry of Health.
Factors associated with health care providers’ practice of smoking cessation interventions in public health facilities in Kiambu County, Kenya Dr Judy.
Quitting smoking is always the best option however, some smokers are not yet ready or willing to quit and continue to inflict harm on themselves and the.
Policies for helping smokers who cannot quit: a prerequisite for maximum prevention of tobacco induced diseases Lars M. Ramström Institute for Tobacco.
Efficacy of Combination First Line Agents for Smoking Cessation Sneha Baxi, Pharm.D. Pharmacy Practice Resident University of Illinois at Chicago.
-Tobacco is the leading preventable cause of disease, disability, and death in the United States (NIDA, 2012). -About 1 in every 5 deaths in the U.S. result.
CAPSTONE PROJECT. Setting the scene- why smoking cessation is important in the treatment of COPD.
1 Behaviour change in theory and in real life Robert West University College London Stockholm, April 2008.
Hazelden Your Next Step Tobacco Recovery Program National Conference on Tobacco or Health Presented by Barry McMillen, MA, LADC, TAS.
Effectiveness of interventions to aid smoking cessation Robert West University College London September 2008.
Acute exercise effects on craving and withdrawal symptoms among women attempting to quit smoking using nicotine replacement therapy Dr. Therese Harper.
Addressing Tobacco Use in Mental Health Settings Pharmacotherapy Materials Prepared By: Center for a Tobacco-Free Finger Lakes University of Rochester.
1 Advising smokers on optimum pharmacotherapy for smoking cessation University College London April 2014 Robert West.
Addressing Tobacco Use in Medical Settings Pharmacotherapy Materials Prepared By: Center for a Tobacco-Free Finger Lakes University of Rochester School.
1 Cancer Research UK smoking cessation programme at UCL: Robert West University College London London October 2007.
By Lucas and Will.  Tobacco smoking can be defined as: Inhaling smoke from prepared burned dried leaves of the tobacco plant, mostly in the form of cigarettes.
1 What happens to smokers in the first few weeks after stopping smoking? Robert West University College London Practical Cardiology, Oxford September 2007.
Smoking. Why people smoke and find it difficult to stop Smoking is an addictive habit. It is associated with strong cravings, dependency, tolerance, and.
AN EXAMINATION OF THE PRACTICE OF TAILORING SMOKING CESSATION PHARMACOTHERAPY IN A TOBACCO TREATMENT PROGRAM WITHIN MENTAL HEALTH AND ADDICTIONS SETTINGS.
Conclusions and Awards
Quick overview of quit smoking counseling for people with mental health or substance use disorders Associate Professor of.
Smoking Cessation Medication
6 myths and facts about tobacco use disorder in people with mental health and substance use disorders Associate Professor.
Anita R. Webb, PhD JPS Family Medicine Residency
Assistant professor Family Medicine - Suez Canal University
Meta-analysis of Effectiveness of First-Line Smoking Cessation Pharmacotherapies 6 Months After Quitting Medication Estimated OR (95% CI) Est. abstinence.
Why and How to Quit Smoking
Robert West University College London WCTOH Washington 2006
Behavioural and pharmacological approaches to treating smokers
Get smoker to their baseline for their behavioral health condition and initiating abstinence from substances. Then assess whether, in the past year, was.
Tobacco Cessation Guidelines for COPD
Forming a Tobacco Addiction
The Burden of Tobacco Use
Nicotine replacement therapy
Pathways to Quit: Options for Smoking Cessation Strategies
Presentation transcript:

A Clinical Flow-Chart for the “Treatment-Resistant Smoker” Renee Bittoun

Background Most smokers want to quit (Fong, 2004) Very few do not (about 6% in Australia) Many/most fail at quit attempts with or without pharmacotherapies (Cohrane Reviews)

WHO: International Framework Convention on Tobacco Control, 2005 The Framework Convention on Tobacco Control (FCTC): Article 1. Section D. harm reduction strategies to improve the health of a population by eliminating or reducing their consumption of tobacco products

Background to harm-reduction Using pharmacotherapies while smoking  inhaled toxicants (Fagerstrom,2002) Potential gateway to quitting (Fagerstrom, 2005; Hughes, 2005) Harm-reduction agenda a softer, not the “stop smoking or you’ll die” dogma of abrupt quitting (Warner, 2005)

Benefits of using NRT for Harm-reduction and Temporary Abstinence Relief of craving and other withdrawal symptoms Reduced cigarette consumption and prevention of compensatory smoking Smokers may learn that they can manage without tobacco for several hours   motivation to quit

Back ground to combination therapies Combination therapies show good outcomes in “hard-to-treat” smokers (Bittoun, 2005)

A flow chart has been developed for clinicians that directs management of the difficult smoking patient: from the disinterested to the poor responders The flow-chart shows increasing therapies as required, using clinical signs and symptoms (withdrawal) to guide treatment choices

Application Apply strategies, both NRT and smoking---to mental health/intellectually disabled smokers 90% comorbid COPD patients using combination/harm reduction

Some Results 16% no pharmacotherapies 16% oral NRT (gum,lozenge) 16% on 2 X 21mg patch 21% on 2 X 21mg patch plus oral NRT 5% on 3 X 21mg patch 5% on Bupropion 1% on Bupropion plus 21mg patch 20% lost to follow-up

Reconciliation Many do not have the “wherewithal” to quit as:- too hard (overwhelming withdrawals) pharmacotherapies too expensive limited understanding of withdrawals Akrasia (lack of will-power, inability to reconcile your want/need with your action, loss of control=addictive behaviour) (Aristotle, 4BCE; Heather, 1998; Ainslie, 2001) Harm-reduction may be a softer option

CONCLUSION Don’t abandon the “hard-to-treat” “can’t quit” smoker Develop a hierarchy of strategies for smokers that begins with permanent cessation using increasing combinations as required but---- Consider harm-reduction for resistant smokers ?? Unethical to exclude recommending harm reduction behaviours to resistant smokers as an alternative to the “Quit or You’ll Die” Dogma.